| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Michael Weiser is Director at TCRT and has filed Form 4s across 2 companies. Michael Weiser's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.4M at current prices.
The biggest single holding is IOVA (~$995K) as Director. Net of sales, the IOVA filings show accumulation of 10,000 shares.
Michael Weiser has 18 Form 4 filings on record from December 2015 to June 2026, across 2 companies: Director at Iovance Biotherapeutics (IOVA), 2018–2026; Director at Alaunos Therapeutics (TCRT), 2015–2017.
The 25 reported transactions were 11 option or other derivative awards, 6 tax withholdings, 3 stock awards and 3 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $68K and no sales.
The only open-market purchase was 10,000 shares of IOVA at an average $6.80 on May 31, 2022, about $68K. Twelve months later IOVA was up 29%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 31, 2022 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 10,000 | $6.80 | $67,978.13 | +9.7% | +58.5% | +29.5% |